

RE: Lonafarnib - Mozilla Thunderbird

ファイル(F) 編集(E) 表示(V) 移動(G) メッセージ(M) ツール(T) ヘルプ(H)

受信 作成 チャット アドレス帳 タグ

差出人 Leslie Gordon <lgordon@progeriaresearch.org> ★

返信 全員に返信 転送 その他

件名 RE: Lonafarnib

2021/10/20 1:44

宛先 (自分) ★

Cc Audrey Gordon at Progeria Research ★, Eleanor Maillie <EMaillie@progeriaresearch.org> ★, Kelsey Tuminelli <ktuminelli@progeriaresearch.org> ★

すべて表示 (あと1件)

Dear Dr. Matsuo,

I will do whatever I can to help you with this approval process, but I may need more detail to understand exactly how I can be most helpful.

Here is information on the number of clinical trial participants from Japan. We cannot provide more detail about ages since this might violate our HIPAA rules.

Lonafarnib Only Trial 1

One female participant from Japan (F1)

Triple Therapy Trial 2

Two female participants from Japan (F1 and F2)

Triple Therapy Trial 2, monotherapy extension

Three female participants from Japan (F1, F2, and F3)

Everolimus and Lonafarnib Trial 3

Two female participants from Japan (F1 and F3)

Everolimus and Lonafarnib Trial 3, monotherapy extension

One female participant from Japan (F3)

Please let us know what additional information you are hoping we can supply for you.

Best regards,
Dr. Leslie Gordon

Leslie B. Gordon, MD, PhD
Professor of Pediatrics Research

Warren Alpert Medical School of Brown University and Department of Pediatrics, Hasbro Children's Hospital, Providence, RI
Department of Anesthesia, Boston Children's Hospital and Harvard Medical School, Boston, MA

Medical Director, The Progeria Research Foundation

Phone: 978-535-2594
Fax: 508-543-0377
Email: LGordon@progeriaresearch.org

Confidentiality Notice: The information contained in this e-mail and any attachments are intended for the exclusive use of the addressees and may be legally privileged and confidential. If you are not an intended recipient, you are hereby notified that any dissemination, distribution or copying of this e-mail and any attachments is strictly prohibited. If you received this e-mail in error, please immediately notify the sender by return e-mail and permanently delete the e-mail and any attachments immediately. You should not retain, copy or use this e-mail or any attachment for any purpose, nor disclose all or any part of the contents to any other person. Thank you.

From: 松尾 宗明 [mailto:matsuo@cc.saga-u.ac.jp]

matsuo@cc.saga-u.ac.jp アカウントを更新しました